Home
About
Overview
Sharing Data
ORCID
Help
History (92)
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
Designing food structure and composition to enhance nutraceutical bioactivity to support cancer inhibition.
Reviewing concomitant medications for participants in oncology clinical trials.
Runx2-Smad signaling impacts the progression of tumor-induced bone disease.
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
See All 92 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
Looyenga BD, Cherni I, Mackeigan JP, Weiss GJ. Tailoring tyrosine kinase inhibitors to fit the lung cancer genome. Transl Oncol. 2011 Apr 01; 4(2):59-70.
View in:
PubMed
authors with profiles
Glen Weiss MD, MBA